Transaction #15901 · Form 4 · 0001794362-25-000005
Vistagen Therapeutics, Inc. · Stock award · Common Stock (Right to Buy)
Vistagen Therapeutics, Inc. · Transacted December 1, 2025 · Filed December 4, 2025
What does this filing report?
An SEC Form 4 filing for Vistagen Therapeutics, Inc. records a stock award involving Common Stock (Right to Buy) on December 1, 2025. The reported quantity was 150,000. The filing date is December 4, 2025. This is one transaction record; amounts are not allocated among any joint reporting owners.
The acquisition category describes how securities were received. It does not by itself establish a cash purchase of common stock. Read the transaction code definitionsand the original filing before interpreting the amounts.
Transaction details
- Company
- Vistagen Therapeutics, Inc.
- Company CIK
- 0001411685
- Security type
- Derivative
- Acquisition type
- Stock award · Code A
- Quantity acquired
- 150,000
- Reported price
- Not reported · See footnotes
- Reference value
- Not reported
- Currency
- Currency not specified
- Ownership
- Direct
- Holdings after transaction
- 150,000
- Ownership description
- Not reported
- SEC acceptance time
- Dec 4, 2025, 6:07 AM EST
- 10b5-1 indication
- Not indicated
Reference value is reported quantity × reported price. It is not a confirmed cash payment or an estimate of a derivative's economic value. A missing currency is not assumed to be USD.
Reporting owners
- Tressler Nick B. ↗
Chief Financial Officer
CIK 0001794362
These are the reporting owners named in the filing. Quantities and amounts are not allocated among co-reporters. Roles reflect this filing, not a current profile.
Company listings
This transaction is not mapped to a specific company listing.
Derivative terms
- Underlying security
- Common Stock
- Underlying quantity
- 150,000
- Conversion / exercise price
- 4.43
- Exercise date
- Not reported
- Expiration date
- December 1, 2035
Filing footnotes & remarks
- F1
- 25% of the stock options vest on June 23, 2026 (the "Vesting Start Date") and 1/36th of the remaining number of shares vest monthly thereafter until all awarded shares are fully vested three (3) years after the Vesting Start Date.
- F2
- The stock options were granted in connection with the Reporting Person's appointment as Chief Financial Officer.
Footnotes are reproduced as plain text from the current source filing. For the full context, read the original SEC filing.
This record was updated Eastern Time. This is the stored record update time, not the transaction date. Report a correction.